Inflammation is responsible for systemic bone loss in patients with seropositive rheumatoid arthritis treated with rituximab

BACKGROUND/AIMS: We investigated the effect of rituximab on systemic bone metabolism in patients with seropositive rheumatoid arthritis (RA). METHODS: Twenty seropositive patients with RA were enrolled and administered one cycle of rituximab. If RA became active for > 6 months after the first rit...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Mie Jin, Jung, Kyong-Hee, Kwon, Seong-Ryul, Park, Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association of Internal Medicine 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10636556/
https://www.ncbi.nlm.nih.gov/pubmed/37867140
http://dx.doi.org/10.3904/kjim.2023.080

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10636556/
https://www.ncbi.nlm.nih.gov/pubmed/37867140
http://dx.doi.org/10.3904/kjim.2023.080

Ejemplares similares